The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2016 | Results of Phase III POLLUX trial on daratumumab in multiple myeloma
Noopur Raje, MD from the Massachusetts General Hospital, Boston, MA gives an overview of the Phase III POLLUX trial on (NCT02076009) on combining daratumumab with lenalidomide and dexamethasone vs lenalidomide and dexamethasone in relapsed/refractory multiple myeloma (MM) presented at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark. According to Dr Raje, patients who received daratumumab with lenalidomide and dexamethasone had more than a doubling in response rate; progression-free survival (PFS) and duration of response are also striking. The future is going to be drug combinations according to Dr Raje. She also highlights the CASTOR trial (NCT02136134) presented at ASCO 2016, which looks at the combination of daratumumab with bortezomib and dexamethasone vs bortezomib and dexamethasone.
